I'm talking about Axsome Therapeutics ( AXSM -0.69% ) and CRISPR Therapeutics ( CRSP -0.50% ). Axsome launched its first two products last year -- and may have more on the way. CRISPR recently requested regulatory approval for a product candidate with blockbuster potential. Which of these innovative biotechs makes the better buy right now? Let's find out.